Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Receivables (2021 - 2025)

Historic Receivables for Pharmaceuticals (CASI) over the last 5 years, with Q2 2025 value amounting to $5.4 million.

  • Pharmaceuticals' Receivables fell 9992.09% to $5.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.4 million, marking a year-over-year decrease of 9992.09%. This contributed to the annual value of $15.3 million for FY2024, which is 9984.86% down from last year.
  • As of Q2 2025, Pharmaceuticals' Receivables stood at $5.4 million, which was down 9992.09% from $7.6 billion recorded in Q1 2025.
  • Over the past 5 years, Pharmaceuticals' Receivables peaked at $12.5 billion during Q2 2023, and registered a low of $5.4 million during Q2 2025.
  • For the 5-year period, Pharmaceuticals' Receivables averaged around $4.1 billion, with its median value being $15.3 million (2024).
  • Data for Pharmaceuticals' Receivables shows a peak YoY increase of 12518849.32% (in 2025) and a maximum YoY decrease of 9992.09% (in 2025) over the last 5 years.
  • Over the past 5 years, Pharmaceuticals' Receivables (Quarter) stood at $9.8 million in 2021, then skyrocketed by 32.34% to $13.0 million in 2022, then skyrocketed by 78046.92% to $10.1 billion in 2023, then crashed by 99.85% to $15.3 million in 2024, then tumbled by 65.05% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q2 2025, $7.6 billion for Q1 2025, and $15.3 million during Q4 2024.